Sheila Frame, vice president and head of biopharmaceuticals, North America, at Sandoz, discusses how biosimilars can increase patient access to treatment.
Transcript:
So in terms of access, I think we have great data now from Europe to show the number of additional patients who get treated. I think people will say to you, hey, Americans, generally speaking, have pretty good access compared to another country where it might be a single-payer system where they rely much more heavily on supply constraints, in the United States typically we don’t have supply constraints, because it's a copay, right?
So the patient doesn't know exactly what the cost of the medication is or what their coverage is or whatever. They just have a copay. I think though, increasingly, as we get more and more transparency in the system and you've heard now some of our big insurers and big pharmacy benefit managers are now actually saying, hey, we're actually willing to share the savings with patients directly, with providers who are infusing these products.
I think that there's a question mark in the United States as to how much more access we'll get, but I do believe, with the number of people who may not have great coverage, that they will now potentially be able to access these products. And I think that's exciting. I really do. I think it'll benefit society.
You know, when I think about rheumatoid arthritis, how many people do you see today who have been crippled by rheumatoid arthritis? Not so many, right? Because of biologics and the value they bring. And I think we probably all can imagine, whether it's a grandmother or a great aunt or whatever who had serious debilitating [disease], lived with pain, all of that kind of thing. The earlier you treat with biologics, then the less and less we've seen from that. So they're incredible innovations, and you don't want anybody to have to go through that if they don't have to.
So I think that's the opportunity from an access perspective. Now, we have great evidence in Europe where there's lots of people who otherwise wouldn't have had access, were treated for years on less expensive medications who then were able to get to biologics because of biosimilars. I think we all have that hope for the United States as well.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.